SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials



Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM
et al (show 5 more authors) (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). 31 - 39.

[img] Text
SGLT2i_MetaAnalysis - Lancet Final accepted version.docx - Accepted Version

Download (1MB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 22 Nov 2018 10:31
Last Modified: 13 May 2022 13:10
DOI: 10.1016/S0140-6736(18)32590-X
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3029006